SymBio Pharmaceuticals Limited (4582) Other
Market cap
¥6.6B
P/E ratio
-1.3x
Symbiopharm develops drugs for rare diseases in cancer and viral infections, focusing on compounds with proven human efficacy to reduce development risks.
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Return on Assets | - | - | - | - | -25.3 | -6.7 | -7.8 | -15.5 | -12.8 | -24.2 | 27.6 | 12.5 | -12.6 | -15 | -27.4 |
| Return on equity (%) | - | - | - | ||||||||||||
| Employees | 71 | 76 | 72 | 69 | 74 | 77 | 78 | 90 | 107 | 127 | 141 | 122 | 109 | 108 | 91 |